IL17A and cancer: IL-17-dependent STAT3/GIV signaling pathway is responsible for VEGF release from cancer cells and promotion of tumor angiogenesis, and GIV expression positively correlates with IL-17+ cell presence and increased microvessel densities and predicts poor survival of NSCLC patients (154).